Psoriatic Arthritis
main-banner
Psoriatic Arthritis
IM011-054 Enrolling

Research Trial for Psoriatic Arthritis (60 Weeks)


Age: 18 Years

Adults aged 18 and over diagnosed to have Psoriatic Arthritis (PsA) for at least 3 months in duration, may be eligible for this study. Individuals must have active plaque psoriatic skin lesion(s) or a documented medical history of plaque psoriasis at screening, along with active arthritis as shown by 3 or more swollen joints and 3 or more tender joints.

Participants will receive investigational oral medication (active study drug) or placebo, during the placebo-controlled period. All participants will then receive active study drug during the active study treatment period. Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses will also be provided.

Study participation will last about 60 weeks and involve about 15 visits to the study centre.


Official Title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

ClinicalTrials.gov ID

NCT04908202

Sponsor

Bristol-Myers Squibb

Study Description

  • Brief Summary:

    Bristol-Myers Squibb

  • Condition or Disease:

    Psoriatic Arthritis

  • Intervention/Treatment:

    Drug: Deucravacitinib Other: Placebo
  • Phase:

    Phase 3

  • Ages Eligible for Study:

    18 Years and older (Adult,Older Adult)

  • Sexes Eligible for Study:

    All

Inclusion Criteria:

Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at screening
Meets the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at Screening
Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at screening
Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and day 1
Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening
≥ 1 PsA-related hand and/or foot joint erosion on X-ray during Screening Period that is confirmed by central reading

Exclusion Criteria:

Nonplaque psoriasis at screening or day 1
Other autoimmune condition such as systemic lupus erythematous, mixed connective tissue disease, multiple sclerosis, or vasculitis
History of or current inflammatory joint disease other than PsA (e.g., gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease)
Active fibromyalgia
Received an approved or investigational biologic therapy for the treatment of PsA or PsO

Other protocol-defined inclusion/exclusion criteria apply


Participating Locations

COUNTRY
country-icon
Australia

Participating Experts

Dr. Lynda Spelman

Dermatologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found
about-icon

Learn More About

Psoriatic Arthritis

Psoriatic arthritis is a type of arthritis associated with the skin condition psoriasis. Psoriasis lesions usually appear as dry, red, scaly patches and may occur anywhere on the body. Arthritis causes swelling, pain, stiffness, and tenderness of the joints. Psoriatic arthritis is a persistent condition characterized by inflammation of the skin (psoriasis) and joints (arthritis). Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials

Filter By Keyword

Trial Name, Intervention and or Treatment, Trial Number, Reference Number, Study Info, Sponsors Phase, and Status.